Evidence map›Paper›PMID 15013994›Full record

Trial reportClinical and diagnostic laboratory immunology2004

Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions.

Philip E Castle, Ana-Cecilia Rodriguez, Frederick P Bowman, Rolando Herrero, Mark Schiffman, M Concepcion Bratti, Lidia Ana Morera, Danny Schust, Peggy Crowley-Nowick, Allan Hildesheim

Registry-linked trialOpen access · diamondAbstract readClinical TrialComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical and diagnostic laboratory immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05334706 (A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05334706 phase4recruitingnot on this mapstarted 2022, after this paper: background citation

A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women After Vaccination With 9vHPV, a Multivalent L1 Virus-like Particle Vaccine, Evaluated in Cervical, Anal and Oral Samples Obtained After One, Two, and Three Vaccine Doses (RIFT-HPV1/RIFT-HPV2)

TypeinterventionalSponsorMiquel Angel Pavon RibasRan2022 to 2026Enrolled69ConditionsCervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18ArmsNonavalent HPV vaccine (9vHPV/Gardasil-9™).
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Characterization of the Genital Microenvironment of Female Rhesus Macaques Prior to and After SIV Infection.American journal of reproductive immunology (New York, N.Y. : 1989) · 2015
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Philip E CastleDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-7234, USA. castlep@mail.nih.gov
Ana-Cecilia Rodriguez
Frederick P Bowman
Rolando Herrero
Mark Schiffman
M Concepcion Bratti
Lidia Ana Morera
Danny Schust
Peggy Crowley-Nowick
Allan Hildesheim
Division of Cancer Epidemiology and GeneticsGuanacaste Conservation Area · CRBrigham and Women's Hospital · USUnited States Department of Health and Human Services · US

Funding

Human papillomavirus (HPV) infection and cervical and anal cancersZIACP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI WENTZENSEN, NICOLAS · 2009 to 2025
$17.3M
CERVICAL CANCER AND HUMAN PAPILLOMAVIRUS (HPV) INFECTIONZ01CP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SCHIFFMAN, MARK · 1996 to 2008
$3.0M
6 · The paper itself

Abstract

Measurements of cervical immunity are important for evaluating immune responses to infections of the cervix and to vaccines for preventing those infections. Three ophthalmic sponges, Weck-Cel, Ultracell, and Merocel, were loaded in vitro with interleukin-1 beta (IL-1 beta), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-15, IL-18, gamma interferon (IFN-gamma), granulocyte-macrophage colony-stimulating factor (GM-CSF), immunoglobulin A (IgA), or IgG, and sponges were extracted and evaluated for total recovery by enzyme-linked immunosorbent assay (ELISA). There was excellent (>75%) recovery for all immune markers from all three devices except for IL-6, which was poorly recovered (<60%) for all sponge types, IFN-gamma, which was poorly recovered from both Weck-Cel and Ultracell sponges but was completely recovered from Merocel sponges, and IL-4, which was poorly recovered from Weck-Cel sponges but was completely recovered from Ultracell or Merocel sponges. We then compared the absolute recovery of selected markers (IL-10, IL-12, IgG, and IgA) from cervical secretion specimens collected from women using each type of sponge. There were no significant differences in the recoveries of IL-10, IL-12, and IgG from cervical specimens collected by any type of ophthalmic sponge, but there was reduced IgA recovery from Merocel sponges. However, the variability in these measurements attributable to sponge types (1 to 3%) was much less than was attributable to individuals (45 to 72%), suggesting that differences in sponge type contribute only in a minor way to these measurements. We infer from our data that the three collection devices are adequate for the measurements of IL-1 beta, IL-2, IL-5, IL-12, IL-15, IL-18, and IgG. Merocel may be a better ophthalmic sponge for the collection of cervical secretions and measurements of IL-4, IL-8, IL-10, GM-CSF, and IFN-gamma, but our data from clinical specimens, not in vitro-loaded sponges, suggested the possibility of reduced recovery of IgA. These findings require confirmation.

Indexed as

AdultBiomarkersCervix UteriFemaleHumansImmunoglobulin AImmunoglobulin GInterleukin-10Interleukin-12Middle AgedSurgical SpongesUterine Cervical DiseasesVaccinesBiomarkersImmunoglobulin AImmunoglobulin GInterleukin-10Interleukin-12Vaccines

Identifiers

PMID15013994
PMCPMC371211
OpenAlexW2106596067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.